Sudeep Pharma (SUDEEPPHRM) Share Price Falls for Second Straight Session
- September 10, 2026
- Posted by: Harsh Piplani
- Category: News
What the Consecutive Declines Show
The Sudeep Pharma Share Price Fall Streak is the key development because it captures both magnitude and persistence. From the streak start base price of Rs 1,342.95, the stock has declined 9.74% across two consecutive sessions and now sits at Rs 1,212.2. That is a sharper read than today’s 5.00% move alone, because it shows that the weakness did not begin and end in one trading day.
The structure of the latest session also adds to that reading. The stock opened at Rs 1,229.9, traded as high as Rs 1,257.8, and still closed at Rs 1,212.2, which was the intraday low. When a stock finishes at the bottom of its day range during a second straight lower close, it points to persistent downside pressure within the available price data. The latest decline also leaves the stock trading below the day’s opening level by the close, reinforcing the weak end-of-session tone.
The bigger point for Univest readers is that the fall streak is now a live trend, not a one-session reaction. The first lower close set the sequence in motion, and the second straight session confirmed that the pressure has remained in place. That is why the Sudeep Pharma Share Price Fall Streak deserves closer attention than a headline about a single 5% decline.
Sudeep Pharma (SUDEEPPHRM) Share Price Fall Streak: Consecutive Decline Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,212.2 |
| Previous Close | Rs 1,276 |
| Today's Move | -Rs 63.80 (-5%) |
| Open | Rs 1,229.9 |
| High | Rs 1,257.8 |
| Low | Rs 1,212.2 |
| Turnover | Rs 1.69 crore |
| Market Capitalisation | Rs 15,168.44 crore |
Sudeep Pharma (SUDEEPPHRM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 15,168.44 crore |
| P/E Ratio | 78.91x |
| P/B Ratio | 15.6x |
| ROE | 25.37% |
| ROCE | 28.5% |
| EPS | Rs 16.17 |
| Book Value Per Share | Rs 81.8 |
| Dividend Yield | 0.12% |
Sudeep Pharma Fundamental Analysis shows a company with strong profitability metrics, but also a rich valuation relative to many industry benchmarks. The company’s market capitalisation is Rs 15,168.44 crore, and the stock trades at a P/E ratio of 78.91 and a P/B ratio of 15.6. Those are substantial multiples and they place valuation at the centre of the current Sudeep Pharma Stock Analysis.
Profitability, however, is also strong on the supplied numbers. Return on equity is 25.37% and return on capital employed is 28.5%, both of which indicate efficient capital use. EPS stands at Rs 16.17, showing the earnings attributable to each share, while book value per share is Rs 81.8, giving the accounting net worth behind each share. The dividend yield is 0.12, which is modest and signals a historical payout relative to the current stock price.
Taken together, the data suggests that investors are not looking at Sudeep Pharma solely as a low-multiple pharma stock. Instead, the market is assigning a premium valuation while also recognising above-benchmark returns. That balance between high multiples and strong profitability is central to how Univest readers should interpret the current Sudeep Pharma Share Price Fall Streak.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 78.91x |
| Benchmark Median P/E | 32.79x |
| Benchmark Average P/E | 49.1x |
| Benchmark P/E Range | 3.4x to 706.55x |
| Company P/B Ratio | 15.6x |
| Benchmark Median P/B | 3x |
| Benchmark Average P/B | 4.44x |
| Company ROE | 25.37% |
| Benchmark Median ROE | 11.83% |
| Benchmark Average ROE | 11.27% |
| Company ROCE | 28.5% |
| Benchmark Median ROCE | 13.75% |
| Benchmark Average ROCE | 13.75% |
| Company Market Capitalisation | Rs 15,168.44 crore |
| Benchmark Median Market Cap | Rs 759.52 crore |
| Benchmark Average Market Cap | Rs 14,312.16 crore |
Sudeep Pharma operates in Healthcare within the Pharmaceuticals & Drugs industry, and the sector benchmark data helps frame whether the stock’s valuation and returns are unusual. The benchmark scope is the same industry and covers 200 companies, giving a broad comparison base rather than a narrow peer set.
On valuation, Sudeep Pharma’s P/E ratio of 78.91 is well above the industry median of 32.79 and the average of 49.1. It still sits within the benchmark range of 3.4 to 706.55, but clearly in the higher end of the industry distribution. The P/B ratio of 15.6 is also above the industry median of 3 and average of 4.44, within a range of -11.34 to 26.81. That points to a premium market valuation versus much of the same-industry universe.
Profitability tells a different story. Sudeep Pharma’s ROE of 25.37% is far above the industry median of 11.83% and average of 11.27. Its ROCE of 28.5% is also above the industry median and average of 13.75. On size, the company’s market capitalisation of Rs 15,168.44 crore is above the industry median of Rs 759.52 crore and slightly above the average of Rs 14,312.16 crore. For readers on Univest, the sector picture is clear: the stock is priced at a premium, but the profitability data also sits comfortably above the industry benchmark.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,51,338.9 | 37.06 | 5.18 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,54,068.03 | 86.06 | 14.25 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,88,767.06 | 86.01 | 20.9 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,14,712.94 | 24.95 | 4.18 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,11,803.57 | 32.79 | 3.14 | 11.83 | 16 |
Sudeep Pharma Share Price Fall Streak is drawing attention partly because the company’s valuation and return profile sits in an interesting position against large listed pharma peers. Compared with Sun Pharmaceutical Industries, Sudeep Pharma trades at a much higher P/E of 78.91 versus 37.06 and a much higher P/B of 15.6 versus 5.18, while also posting stronger ROE and ROCE than Sun’s 14.85% and 19.11%.
Against Divi’s Laboratories and Torrent Pharmaceuticals, Sudeep Pharma’s P/E is slightly lower than 86.06 and 86.01 respectively. Its P/B of 15.6 is above Divi’s 14.25 but below Torrent’s 20.9. On profitability, Sudeep Pharma’s ROE of 25.37% is above Divi’s 16.19% but below Torrent’s 26.76%, while its ROCE of 28.5% is ahead of both at 21.51% and 19.27%.
Versus Zydus Lifesciences and Cipla, the contrast is sharper. Both trade at materially lower P/E and P/B multiples, but also report lower ROE and ROCE. Market-cap-wise, Sudeep Pharma at Rs 15,168.44 crore is much smaller than all five comparison names, which range from Rs 1,11,803.57 crore to Rs 4,51,338.9 crore. That leaves the stock positioned as a smaller company carrying premium valuation multiples alongside strong return ratios.
Why Investors Are Watching Sudeep Pharma
The latest Sudeep Pharma Share Price Fall Streak matters because it combines a fast short-term decline with premium valuation and strong profitability. Two consecutive lower closes have already cut the stock by 9.74% from the streak base, so the move is large enough to stand out even without a company-specific trigger in the data.
Today’s decline also matters because the stock finished at the low of the session. That tells readers the weakness did not fade before the close. The Sudeep Pharma Share Price Fall Streak therefore reflects ongoing selling pressure across the available sessions rather than a brief intraday slip.
At the same time, the company’s valuation sits above the same-industry median and average, and its return ratios remain strong. That combination helps explain why Sudeep Pharma continues to attract attention on Univest: the stock is declining in the short run, but it is doing so in the context of high multiples, solid profitability and a market capitalisation that remains meaningful within the listed pharma space.
For now, the key development is not just the daily fall but the fact that the decline has repeated. A second straight session of weakness is more telling than a single lower close, and that is why the current Sudeep Pharma Share Price Fall Streak is the central takeaway from the day’s data.
About Sudeep Pharma
Sudeep Pharma is part of the Healthcare sector and operates within the Pharmaceuticals & Drugs industry. Based on the supplied classification, the company sits in a listed pharma universe where investors typically compare valuation, return ratios and market capitalisation against a wide industry set. In the current market context, Sudeep Pharma is being discussed not just for its latest stock move, but for how its pricing metrics and profitability stand against other pharmaceutical companies tracked on Univest.
Track Sudeep Pharma on Univest
On Univest, investors can track Sudeep Pharma Share Price Today along with valuation ratios, market capitalisation, peer comparison and broader market insights. Univest also helps readers follow Sudeep Pharma Stock News, sector context and changes in price action through one consolidated research view without turning the data into a recommendation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Sudeep Pharma falling today?
Ans. The supplied data confirms that Sudeep Pharma closed lower for the second straight session and fell 5.00% today to Rs 1,212.2. It confirms the price pattern, but it does not establish a company-specific cause for the decline.
What is the current Sudeep Pharma Share Price?
Ans. Sudeep Pharma closed at Rs 1,212.2 in the latest session. That was down Rs 63.8 from the previous close of Rs 1,276, marking a 5.00% fall during the day and extending the ongoing two-session decline.
How much has the stock fallen in the current streak?
Ans. The current Sudeep Pharma Share Price Fall Streak totals a 9.74% decline across two consecutive sessions. The move is measured from the streak base price of Rs 1,342.95 to the latest closing price of Rs 1,212.2.
What were the day high and day low for Sudeep Pharma ?
Ans. In the latest session, Sudeep Pharma traded between a day high of Rs 1,257.8 and a day low of Rs 1,212.2. The stock finally closed at Rs 1,212.2, which matched the session low.
What does the latest session show about price action?
Ans. The session opened at Rs 1,229.9, below the previous close of Rs 1,276, and the stock ended at the day’s low of Rs 1,212.2. That pattern points to sustained intraday weakness rather than a late recovery.
How is Sudeep Pharma valued versus its industry?
Ans. Sudeep Pharma trades at a P/E of 78.91 against the same-industry median of 32.79 and average of 49.1. Its P/B of 15.6 is also above the industry median of 3 and average of 4.44.
Are Sudeep Pharma ’s profitability ratios strong?
Ans. The supplied figures show strong profitability. ROE stands at 25.37% and ROCE at 28.5%, both comfortably above the same-industry medians of 11.83% and 13.75%, which supports market attention despite the ongoing decline.
How does Sudeep Pharma compare with major pharma peers?
Ans. Sudeep Pharma trades at higher valuation multiples than peers such as Sun Pharma, Zydus Lifesciences and Cipla, but its ROE and ROCE are also stronger than several of those names. Its market capitalisation remains much smaller.
Track Sudeep Pharma (SUDEEPPHRM) Share Price on Univest
UseSudeep Pharma (SUDEEPPHRM) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.
